Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021

The safety profile of the 9-valent human papillomavirus vaccine (9vHPV) was evaluated based on the reporting rate of adverse events following immunization (AEFI) obtained from the passive surveillance data in Zhejiang. The 9vHPV AEFI reports in Zhejiang were collected and reviewed from the National...

Full description

Bibliographic Details
Main Authors:	Fuxing Chen, Xuejiao Pan, Hui Liang, Lingzhi Shen, Ying Wang, Yaping Chen, Huakun Lv, Yu Hu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	aefi (adverse events following immunization) 9-valent human papillomavirus vaccine post-licensure surveillance safety vaccination
Online Access:	http://dx.doi.org/10.1080/21645515.2022.2152256

Similar Items

Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020
by: Yu Hu, et al.
Published: (2021-12-01)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
by: Yu Hu, et al.
Published: (2022-01-01)

Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system
by: Xuejiao Pan, et al.
Published: (2021-10-01)

Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China
by: Xuejiao Pan, et al.
Published: (2022-01-01)

Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018)
by: Cecilia M. Egoavil, et al.
Published: (2020-03-01)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
by: Yuan Ding, et al.
Published: (2023-08-01)

9-Valent human papillomavirus vaccine: a review of the clinical development program
by: Alain Luxembourg, et al.
Published: (2017-11-01)

Surveillance on the adverse events following immunization in Dazu District of Chongqing， 2016‒2020
by: WANG Qian, et al.
Published: (2022-04-01)

Barriers to healthcare workers reporting adverse events following immunization in Zhejiang province, China
by: Huakun Lv, et al.
Published: (2022-11-01)

Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China
by: Ruogu Meng, et al.
Published: (2023-12-01)

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16–26 years in Chongqing, China
by: Yuan-yuan Zhang, et al.
Published: (2023-12-01)

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
by: Susanne K. Kjaer, et al.
Published: (2021-04-01)

Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia
by: C.-M. Baxter, et al.
Published: (2018-08-01)

Farmacovigilancia de vacunas y su aplicación en Chile
by: Adiela Saldaña, et al.
Published: (2020-05-01)

Does This COVID-19 Pandemic Demand a Scale Up in AEFI Reporting in India?
by: Sadhvika Kanagat, et al.
Published: (2022-09-01)

Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine
by: Huakun Lv, et al.
Published: (2021-11-01)

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
by: Sven-Eric Olsson, et al.
Published: (2020-12-01)

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
by: Katrina M. Nolan, et al.
Published: (2023-04-01)

Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021
by: YANG Shoufei, et al.
Published: (2022-08-01)

Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study
by: Yu Liu, et al.
Published: (2023-07-01)

Vaccine Safety International Monitoring
by: M. A. Darmostukova, et al.
Published: (2019-03-01)

Safety of Monkeypox Vaccine Using Active Surveillance, Two-Center Observational Study in Italy
by: Marco Montalti, et al.
Published: (2023-06-01)

Evaluation of the adverse events following immunization surveillance system in Guruve district, Mashonaland Central 2017
by: Mutata Constantine, et al.
Published: (2018-11-01)

A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
by: Huakun Lv, et al.
Published: (2022-02-01)

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
by: Vu Dinh Thiem, et al.
Published: (2021-07-01)

A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study
by: Mohamed Serhan, et al.
Published: (2024-12-01)

Adverse Events Following Immunization with DTP Vaccine in Infants and Children in Kermanshah City: A Cohort Study
by: M Karami, et al.
Published: (2006-02-01)

Real-Life Safety Profile of the 9-Valent HPV Vaccine Based on Data from the Puglia Region of Southern Italy
by: Antonio Di Lorenzo, et al.
Published: (2022-03-01)

Intussusception and Other Adverse Event Surveillance after Pilot Introduction of Rotavirus Vaccine in Nam Dinh and Thua Thien Hue Provinces—Vietnam, 2017–2021
by: Ly Khanh Thi Le, et al.
Published: (2024-02-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
by: Yunhua Wei, et al.
Published: (2022-11-01)

Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases
by: Hossein Azarpanah, et al.
Published: (2021-09-01)

Knowledge, perceptions, and practice towards adverse events following immunization surveillance among vaccination workers in Zhejiang province, China
by: Huakun Lv, et al.
Published: (2023-01-01)

Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics’ impact
by: Ohoud A. Almadani, et al.
Published: (2022-12-01)

Vaccine-associated Arthus reaction
by: Tanatorn Soravipukuntorn, MD, et al.
Published: (2023-09-01)

Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa
by: AbdulAzeez Adeyemi Anjorin, et al.
Published: (2022-04-01)

Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study
by: Kandace L. Amend, et al.
Published: (2022-11-01)

Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy)
by: Pasquale Stefanizzi, et al.
Published: (2023-02-01)

Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States
by: Vincent Daniels, et al.
Published: (2021-07-01)

Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01)